Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501.
Explore how machine learning is revolutionising interstitial lung disease management, enhancing early diagnosis, treatment, ...
Greek yogurt supplementation post-training significantly reduces inflammation markers in young males, offering insights into ...
Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:58 PM EDTCompany ParticipantsMatthew Gline - ...
Among adults with obesity who lost weight after following a low-calorie diet, weight-loss maintenance with exercise was ...
India - Grant Romiplostim Lyophilized Formulations Patent With Amendments: Madras High Court Directs. Legal News and Analysis ...
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event ...
Zacks Investment Research on MSN
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?
Black Diamond Therapeutics, Inc. (BDTX) is a clinical-stage oncology company developing therapies that target families of ...
The EMA’s recommendation marks a key step toward expanding treatment access for patients with psoriasis, psoriatic arthritis, ...
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best healthcare penny stocks to buy now. On September 8, 2025, ImmunityBio Inc.
Immunotherapy has transformed the treatment of cancer, yet many patients do not have response or lasting benefit. Strategies ...
The US healthcare sector is one of the biggest in the world, with spending expected to reach $5.3 trillion this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback